Cue Biopharma, Inc.: BALYASNY ASSET MANAGEMENT L.P. discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Balyasny Asset Management L.P. disclosed a stake exceeding 5% in Cue Biopharma, Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005042). The exact share count and percentage were not specified in the filing headline. The move signals increased institutional interest in the clinical-stage immunotherapy company. Investors will watch for further 13G/13D amendments for precise ownership details and any subsequent changes in Balyasny's position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Balyasny Asset Management L.P., Cue Biopharma, Inc.